Innoviva, Inc. (INVA)
Automate Your Wheel Strategy on INVA
With Tiblio's Option Bot, you can configure your own wheel strategy including INVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INVA
- Rev/Share 5.8893
- Book/Share 11.3707
- PB 1.5188
- Debt/Equity 0.6308
- CurrentRatio 2.6435
- ROIC 0.0012
- MktCap 1088372912.0
- FreeCF/Share 3.1233
- PFCF 5.5432
- PE 28.0907
- Debt/Assets 0.3381
- DivYield 0
- ROE 0.0568
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | INVA | Goldman | -- | Sell | -- | $17 | Sept. 30, 2025 |
| Initiation | INVA | Oppenheimer | -- | Outperform | -- | $45 | Aug. 11, 2025 |
| Initiation | INVA | H.C. Wainwright | -- | Buy | -- | $40 | July 14, 2025 |
| Initiation | INVA | Cantor Fitzgerald | -- | Overweight | -- | $26 | July 11, 2025 |
| Initiation | INVA | Scotiabank | -- | Sector Outperform | -- | $55 | March 7, 2025 |
News
Antheia Appoints Eric d'Esparbes as Chief Financial Officer
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral
d'Esparbes to lead Antheia's financial strategy as the company continues its global expansionand commercialization MENLO PARK, Calif. , Oct. 21, 2025 /PRNewswire/ -- Antheia , the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the appointment of Eric d'Esparbes as Chief Financial Officer.
Read More
Are Investors Undervaluing Innoviva (INVA) Right Now?
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Innoviva to Participate in Upcoming Investor Conferences
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 46th Annual Global Healthcare Conference 2025 Form.
Read More
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
Published: March 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral
If you work in the biotech industry, you might know the name Alex Denner.
Read More
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
Published: February 26, 2025 by: Business Wire
Sentiment: Neutral
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted select corporate progress and achievements. Pavel Raifeld,.
Read More
About Innoviva, Inc. (INVA)
- IPO Date 2004-10-05
- Website https://www.inva.com
- Industry Biotechnology
- CEO Pavel Raifeld
- Employees 127